Healthcare Services

Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Set for Strong Expansion Reaching $6.37 Billion by 2030 at 10.4% CAGR

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market By The End Of 2030?

The market for cancer anorexia-cachexia syndrome (CACS) has seen rapid expansion over recent years. It is forecast to rise from $3.88 billion in 2025 to $4.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This growth historically stems from factors including the increasing occurrence of advanced cancer cases, a heightened understanding of cachexia’s effect on treatment results, the early adoption of appetite stimulants in clinical practice, an increase in hospital-based supportive care initiatives, and the broadening of oncology nutrition research.

The market for cancer anorexia-cachexia syndrome (cacs) is projected to experience substantial expansion over the upcoming years, with an anticipated value of $6.37 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.4%. This projected growth is driven by factors such as increased funding for cachexia drug development, a heightened emphasis on personalized oncology supportive care, greater activity in clinical trials for new therapeutic agents, the broadening of home-based cancer care services, and the deeper incorporation of cachexia management strategies into standard oncology protocols. Key trends anticipated during this period encompass the development of more targeted therapies for cachexia, a growing interest in anti-inflammatory treatment methods, wider acceptance of combination therapeutic strategies, the proliferation of nutritional and metabolic support options, and a stronger focus on early intervention for cachexia.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

The growing incidence of cancer is expected to drive the expansion of the **cancer anorexia-cachexia syndrome market** in the future. Cancer is a broad categorization for diseases characterized by the unrestrained proliferation and dissemination of abnormal cells throughout the body. Global cancer rates are increasing due to elements like an aging demographic, shifts in lifestyle, environmental exposures, improved detection methodologies, and greater awareness, alongside genetic predispositions and infections linked to certain cancer types. **Cancer anorexia-cachexia syndrome (CACS)** helps tackle this rising cancer prevalence by concentrating on addressing the severe weight loss and malnutrition frequently experienced by cancer patients, thereby enhancing their overall quality of life and treatment outcomes. For instance, in August 2024, a report released by Macmillan Cancer Support, a charitable organization in the **UK**, stated that over **3 million** individuals in the **UK** are living with cancer, a figure projected to climb to **3.5 million** by **2025**, **4 million** by **2030**, and **5.3 million** by **2040**. Thus, the increasing prevalence of cancer is a key factor stimulating the growth of the **cancer anorexia-cachexia syndrome market**. Increasing healthcare expenditure is anticipated to propel the growth of the **cancer anorexia-cachexia syndrome market** moving forward. Healthcare expenditure refers to the aggregate financial resources allocated to healthcare services, encompassing both public and private sector spending. The rise in healthcare expenditure is driven by factors such as an aging population, the increasing incidence of chronic diseases, advancements in medical technology, and a heightened demand for high-quality healthcare services. **Cancer Anorexia-Cachexia Syndrome (CACS)** contributes to increasing healthcare expenditure by requiring specialized treatments, nutritional support, and palliative care for patients, thereby adding to the costs associated with managing cancer-related complications. For example, in May 2024, according to the Office for National Statistics, a **UK**-based government department, total healthcare expenditure recorded a **5.6%** increase in nominal terms from **2022** to **2023**, indicating a notable acceleration compared to the **0.9%** growth observed in **2022**. Consequently, the increasing healthcare expenditure is driving the expansion of the **cancer anorexia-cachexia syndrome market**.

Which Segment Classifications Shape The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –

1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications

2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics

3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions

4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

5) By Application: Hospitals, Clinics, Home Care

Subsegments:

1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators

2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists

3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)

4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors

5) By Other Indications: Combination Therapies, Supportive Care Interventions

What Key Trends Are Influencing The Development Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

Leading companies within the cancer anorexia-cachexia syndrome market are prioritizing the development of innovative solutions, such as monoclonal antibody therapies, to improve the effectiveness of treatments, enhance patient well-being, and address unmet needs in clinical practice. Monoclonal antibody therapies are medical interventions that employ antibodies manufactured in a laboratory setting, specifically designed to target unique antigens on cancer cells, thereby helping the immune system to recognize and attack them more vigorously. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, announced positive results from a Phase II clinical trial involving ponsegromab, a monoclonal antibody specifically targeting Growth/Differentiation Factor 15 (GDF-15). The encouraging data from this study presents new hope for a treatment option for patients grappling with this debilitating condition, for which there are currently few efficacious treatments available. The Phase 2 trial’s findings indicate substantial progress in addressing the underlying inflammatory processes that contribute to muscle wasting and weight loss among cancer patients. This particular treatment approach aims not only to enhance physical function but also to elevate the overall quality of life for cancer patients, marking a significant advancement in oncology care.

Which Companies Are Expanding Their Footprint In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

Read the full cancer anorexia-cachexia syndrome (cacs) market report here:

https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

Which Regions Are Projected To Dominate The Cancer Anorexia-Cachexia Syndrome (CACS) Market In The Coming Years?

North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Anorexia-Cachexia Syndrome (CACS) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2026, By The Business Research Company

Anaphylaxis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

Vulvodynia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Emphysema Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795